Entering text into the input field will update the search result below

Lyra Therapeutics pops 8% on positive LYR-210 results in chronic rhinosinusitis

  • Lyra Therapeutics (NASDAQ:LYRA) perks up 8.3% premarket after announcing positive topline results from the pharmacokinetic (PK) study of LYR-210 in adults with chronic rhinosinusitis (CRS), an inflammatory disease of the paranasal sinuses.
  • The study enrolled 24 patients, half of whom received LYR-210 2500 µg

Recommended For You

More Trending News

About LYRA Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
LYRA--
Lyra Therapeutics, Inc.